TATVANSETATVA CHIN PHARM CHEM LTD· Chemicals & PetrochemicalsHighNeutral
Announced Mon, 19 Oct, 2026 · 15:52 IST

Tatva Chintan Q2 FY27 results: revenue up 76%, PAT up 116% YoY

Revenue Growth 20pctPat Growth 25pctExceptional ItemNegative Operating CashflowResults View source PDFExplain this filing

TATVA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-3.9%Reaction day
₹1914.30
prior close
₹2044.00
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-2.6%-1.3% vs market
Specialty Chemicals peers, median of 100sector-3.3%-0.6% vs sector

On the reaction day the stock moved 1.3 pts less than Nifty Microcap 250 and 0.6 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-1.8
10m
-3.0
15m
-1.8
30m
-3.0
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-3.9-2.6-1.3-3.3-0.6
Next day
-14.1-3.6-10.5-4.3-9.7
2d
-18.2-5.8-12.4-6.9-11.3
3d
-18.5-5.5-13.0-6.5-12.0
4d
-16.4-3.8-12.6-5.4-11.0
5d
-14.6-3.8-10.8-5.3-9.3
1w
-13.8pendingpending-7.1-6.8
15d
—————
1m
—————
2m
—————
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Specialty Chemicals peers, median of 100Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Tatva Chintan Q2 FY26-27 consolidated revenue rose 76% YoY to Rs 217 crore (from Rs 124 crore). PAT more than doubled to Rs 21.5 crore vs Rs 9.9 crore. H1 revenue up 60% to Rs 384 crore; PAT grew 126% to Rs 37.4 crore. Q2 EPS at Rs 9.17. Standalone PAT was Rs 15.4 crore, up 72% YoY. Auditor NDJ and Co issued an unmodified limited review.

Likely market impact

Strong YoY growth in revenue and profit is positive. Rising short-term borrowings and negative H1 operating cash flow are concerns to watch.